Adicet Bio
Develops off-the-shelf gamma delta CAR-T cell therapies for autoimmune disease and cancer.
Something off on this page? Send us feedback.
Profile
Develops allogeneic gamma delta CAR-T cell therapies in clinical development, centered on prula-cel for autoimmune disease and ADI-212 for prostate cancer. The Boston-based company focuses its resources on these programs after discontinuing ADI-270.
Built around an allogeneic gamma delta CAR-T platform, the company develops off-the-shelf cell therapies for autoimmune disease and cancer. The cells are engineered with chimeric antigen receptors. Its current pipeline centers on prulacabtagene leucel, or prula-cel, for autoimmune disease and ADI-212 for metastatic castration-resistant prostate cancer.
Based in Boston, the clinical-stage business concentrated resources on those two programs after discontinuing ADI-270. That pipeline reset narrowed work to autoimmune disease and prostate cancer. Prula-cel and ADI-212 remain development programs rather than approved products, so the business depends on clinical progress for its prioritized candidates.
Company facts
Key statistics
Year to date +2.6% · Average volume (30d) 92.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Jan 6, 2026 | Canaccord Genuity | Reiterate | Buy | $18 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$1.69 | −$1.99 | −17.8% | — | — | — | −13.43% |
| May 13, 2026Q1 FY26 | −$2.93 | −$1.88 | +35.8% | — | — | — | +4.21% |
| Mar 12, 2026Q4 FY25 | −$3.23 | −$2.94 | +9.0% | $2.9M | — | — | +2.41% |
| Nov 5, 2025Q3 FY25 | −$4.16 | −$4.64 | −11.5% | — | — | — | −1.90% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$1.3M | $0 | |
| Operating income | −$29.9M | −$32.4M | −$28.0M | −$31.9M | −$21.6M | −$22.3M | |
| Net income | −$28.2M | −$31.2M | −$26.9M | −$30.5M | −$20.2M | −$21.4M | |
| Diluted EPS | −$4.96 | −$5.44 | −$4.64 | −$2.94 | −$1.88 | −$1.99 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $9.7M · FY22 $25.0M · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $118.2M · Total debt $12.9M · Total assets $148.2M · Shareholders' equity $120.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 9.35M · Float 8.20M · 87.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. · 10 percent owner | 932.6K | 9.98% | Form 4 | Apr 29, 2026 |
| Orbimed Advisors LLC | 844.8K | 8.80% | 13D | Apr 10, 2026 |
| Franklin Resources Inc | 626.6K | 6.70% | 13F | May 13, 2026 |
| Citadel Advisors LLC | 381.8K | 4.08% | 13F | May 15, 2026 |
| Vanguard Capital Management LLC | 336.5K | 3.60% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 18, 2026 | Ra Capital Management, L.P. | 10 percent owner | +74,577 | $7.04 |
| Feb 19, 2026 | Ra Capital Management, L.P. | 10 percent owner | +74,268 | $7.21 |
| Feb 20, 2026 | Ra Capital Management, L.P. | 10 percent owner | +74,751 | $7.27 |
| Apr 8, 2026 | Orbimed Advisors LLC | 10 percent owner | −72,939 | $6.42 |
| Apr 7, 2026 | Orbimed Advisors LLC | 10 percent owner | −31,719 | $6.52 |
Peers
- Allogene Therapeutics
Allogeneic CD19/CD70 CAR-T in autoimmune disease
- Fate
Off-the-shelf CD19 CAR-T for autoimmune disease
- Nkarta
Allogeneic CD19 CAR-NK for autoimmune disease
- Cabaletta Bio
Autologous CD19 CAR-T across autoimmune diseases
- Caribou Biosciences
Allogeneic CAR-T programs for B-cell malignancies
- Cellectis (ADR)
Gene-edited allogeneic CAR-T for B-cell cancers
- IN8bio
Gamma-delta T-cell therapies for cancer and autoimmunity
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Adicet Bio | $9.06 | +0.17% | $84.7M | — | — | — | — |
| Allogene Therapeutics | $2.01 | −0.09% | $697.2M | — | — | 150.3 | — |
| Fate | $2.43 | +0.60% | $283.2M | — | — | 43.6 | +9.2% |
| Nkarta | $2.80 | +1.45% | $197.5M | — | — | — | — |
| Cabaletta Bio | $3.18 | +2.25% | $508.7M | — | — | — | — |
| Caribou Biosciences | $1.65 | +2.17% | $160.7M | — | — | 16.0 | −43.8% |
| Cellectis (ADR) | $3.41 | −0.58% | $341.4M | — | — | 4.5 | −59.2% |
| IN8bio | $1.04 | +0.82% | $9.9M | — | — | — | — |
| Median | — | — | 29.8 | −43.8% |